Concepedia

Author

John A. Glaspy

University of California, Los AngelesORCID

Also Known As

G Rossi, Glaspy, John A, Glaspy, John A., J A Glaspy, J GLASPY, J Glaspy, J. A. Glaspy, J. Glaspy, J.A. Glaspy, JOHN A. GLASPY

718

Publications

38.2K

Citations

89

H-Index

177

Concepts

All Affiliations

University of California, Los AngelesAmgen (United States)UCLA Medical CenterThe University of Texas MD Anderson Cancer CenterUCLA Jonsson Comprehensive Cancer Center
JA

About

John A. Glaspy is an author at University of California, Los Angeles specializing in medicine, oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

42

100

12.2K

2

Health Sciences

21

33

1.3K

3

Engineering

3

3

227

4

Education

1

1

29

5

Nursing

1

1

29

John A. Glaspy

×

206

Publications

34.6K

Citations

82

H-Index

YearCitations

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley,

Nature

2014

6.5K

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Dennis J. Slamon, W. Eiermann, Nicholas J. Robert,

New England Journal of Medicine

2011

2.7K

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

Jeffrey Crawford, Howard Ozer, Ronald G. Stoller,

New England Journal of Medicine

1991

1.4K

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Mark D. Pegram, A. Lipton, Daniel F. Hayes,

Journal of Clinical Oncology

1998

1.1K

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Nicholas J. Robert, Véronique Dièras, John A. Glaspy,

Journal of Clinical Oncology

2011

1.1K

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

Hubing Shi, Willy Hugo, Xiangju Kong,

Cancer Discovery

2013

979

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.

John A. Glaspy, Ronald Bukowski, Douglas Steinberg,

Journal of Clinical Oncology

1997

705

Thrombocytopenia caused by the development of antibodies to thrombopoietin

Junzhi Li, Chun Yang, Yuping Xia,

Blood

2001

678

Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion

Dilprit Bagga, Ling Wang, Robin Farias‐Eisner,

Proceedings of the National Academy of Sciences

2003

628

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

Neil Senzer, Howard L. Kaufman, Thomas Amatruda,

Journal of Clinical Oncology

2009

607

Page 1